SSY GROUP (02005) has obtained the drug production registration approval from the National Medical Products Administration for fumaric acid foscarnet tablets (20mg and 10mg).

SSY GROUP (02005) announced that the Group has obtained the drug production registration approval from the China National Medical Products Administration (NMPA) for fumarate vonoprazan tablets (20mg and 10mg), which belong to Class 4 of chemical drugs and are considered to have passed consistency evaluation. Fumarate vonoprazan tablets are mainly used to treat reflux esophagitis. The Group's fumarate vonoprazan active pharmaceutical ingredients have already been approved and registered by the NMPA for use in market preparations.